Sorafenib treatment alters immunosuppressive phenotypes in hepatocellular carcinoma

July 21, 2016

Hepatocellular carcinoma (HCC) is the most common form of liver cancer and results from long-term damage and fibrosis, such as is caused by chronic alcohol abuse and viral-induced hepatitis. Patients with advanced HCC are often given the drug sorafenib, which targets vascular endothelial growth factor (VEGF) and other kinases to prevent blood vessel growth in the tumor. Recent studies indicate that sorafenib can also alter immune cell function in patients.

In this issue of JCI Insight, Yasmin Thanavala and colleagues at Roswell Park Cancer Institute evaluated the in a small cohort of patients with advanced HCC before and after treatment with .

Sorafenib treatment was associated with a reduction in immune-suppressive phenotypes, including decreased expression of PD-1, which dampens the responsiveness of a group of immune cells that can attack the tumor (known as effector T cells), fewer immune cells that dampen immune responses (regulatory T cells), and lower levels of factors that suppress immune system activity.

Several of these responses were associated with increased overall survival.

Together, the results of this study indicate that evaluation of HCC patient immune phenotypes before and after sorafenib can help predict treatment outcome.

Explore further: Antiviral therapy prolongs survival in immune tolerant hepatitis B patients

More information: Suresh Gopi Kalathil et al, PD-1+ and Foxp3+ T cell reduction correlates with survival of HCC patients after sorafenib therapy, JCI Insight (2016). DOI: 10.1172/jci.insight.86182

Related Stories

Antiviral therapy prolongs survival in immune tolerant hepatitis B patients

April 15, 2016
A new study, presented today at The International Liver Congress 2016 in Barcelona Spain, demonstrates that the use of antiviral therapy for patients in the immune tolerant phase of Hepatitis B (HBV) prolongs overall survival ...

Towards the goal of precision therapy in hepatocellular carcinoma

March 7, 2016
Advances in understanding the molecular genetics of hepatocellular neoplasia have been made, and developing targeted therapeutics in combination with molecular tumor profiling may help accomplish the goal of precision treatment ...

Liver cancers armed with many strategies for evading immune response

April 18, 2013
(Medical Xpress)—Researchers at Roswell Park Cancer Institute (RPCI) have published findings that help explain how a common and particularly resilient form of liver cancer evades the body's natural antitumor responses. ...

Useful markers to predict response to chemotherapy in patients with liver cancer

October 23, 2014
A study led by the researcher at the Institute of Biomedical Research (IDIBELL), Isabel Fabregat, could serve to select patients with hepatocellular carcinoma unresponsive to most frequently used drug in liver cancer: sorafenib. ...

Researchers describe mechanisms that trigger NASH and liver cancer

July 11, 2016
Non-alcoholic steatohepatitis (NASH) is a serious hepatic condition that precedes hepatocellular carcinoma (HCC) and is currently untreatable. A study conducted at the Spanish National Cancer Research Centre (CNIO) shows ...

Cancer cells play hide-and-seek with immune system

June 29, 2016
When the immune system attacks cancer, the tumour modifies itself to escape the immune reaction. Researchers at LUMC published on this subject in Nature on 28 June.

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.